Boiling down the dozen pitches from budding entrepreneurs at Thursday's Startup Bowl reveals vital themes: the mammoth influence of mobile, an intense craving for consumer data, and the relentless pursuit of revenue.
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.